2022
Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy
Denoble A, Moyett J, Goldstein S, Ward CC, Truong T, Erkanli A, James A, Grotegut C. Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy. American Journal Of Perinatology 2022, 40: 467-474. PMID: 35973801, PMCID: PMC10168705, DOI: 10.1055/a-1925-1532.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersComorbidityFemaleHumansNatriuretic Peptide, BrainObesityPeptide FragmentsPregnancyConceptsNT-proBNP levelsBody mass indexProspective observational studyObese patientsNonobese patientsNT-proBNPWeeks postpartumObservational studyN-terminal pro-brain natriuretic peptide levelsN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptide levelsLinear mixed effects modelsLower NT-proBNP levelsHigher systolic blood pressurePro-brain natriuretic peptidePregnant peopleNatriuretic peptide levelsSignificant medical comorbiditiesTime pointsSystolic blood pressureMixed effects modelsEffects modelLogNT-proBNPPP elevationHypertensive disorders
2020
Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease
Goldstein S, D’Ottavio A, Spears T, Chiswell K, Hartman R, Krasuski R, Kemper A, Meyer R, Hoffman T, Walsh M, Sang C, Paolillo J, Li J. Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease. Journal Of The American Heart Association 2020, 9: e016400. PMID: 32654582, PMCID: PMC7660712, DOI: 10.1161/jaha.119.016400.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseSevere congenital heart diseaseMedian ageNonsevere CHDPresence of cardiovascular comorbiditiesHeart diseaseCardiovascular risk factorsNon-CHD causesIschemic heart diseaseElectronic medical record dataDeath certificate dataCause of deathNonsevere diseaseContemporary cohortValvular lesionsCardiovascular comorbidityCardiovascular comorbiditiesResults PatientsCardiovascular deathMedical record dataRisk factorsSevere groupLesion severityPatientsCertificate data
2019
Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
Goldstein S, Green J, Huber K, Wojdyla D, Lopes R, Alexander J, Vinereanu D, Wallentin L, Granger C, Al-Khatib S. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). The American Journal Of Cardiology 2019, 124: 1406-1412. PMID: 31474328, PMCID: PMC7194994, DOI: 10.1016/j.amjcard.2019.07.046.Peer-Reviewed Original ResearchConceptsThyroid disease historyThyroid diseaseAtrial fibrillationDisease historyThromboembolic eventsClinical outcomesOutcomes of atrial fibrillationHistory of thyroid diseaseBaseline characteristics of patientsCox modelBenefits of apixabanOther Thromboembolic EventsCharacteristics of patientsEffects of anticoagulantsAdjusted hazard ratiosBaseline characteristicsCompare outcomesHazard ratioThyroidApixabanPatientsRandomized treatmentWarfarinHypothyroidismDisease